Login to Your Account



More Selling Than Buying

Pharma Outlicensing: From Opportunism to R&D Funding

By Trista Morrison


Monday, May 17, 2010
A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription